99 related articles for article (PubMed ID: 15126875)
1. Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy.
Ringhoffer M; Müller CR; Schenk A; Kirsche H; Schmitt M; Greiner J; Gschwend JE
J Urol; 2004 Jun; 171(6 Pt 1):2456-60. PubMed ID: 15126875
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma.
Dannenmann SR; Hermanns T; Bransi A; Matter C; von Boehmer L; Stevanovic S; Schraml P; Moch H; Knuth A; van den Broek M
Cancer Immunol Res; 2013 Nov; 1(5):288-95. PubMed ID: 24777966
[TBL] [Abstract][Full Text] [Related]
3. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides.
Kawashima H; Obayashi A; Kawamura M; Masaki S; Tamada S; Iguchi T; Uchida J; Kuratsukuri K; Tanaka T; Nakatani T
BJU Int; 2014 Feb; 113(2):320-32. PubMed ID: 24895689
[TBL] [Abstract][Full Text] [Related]
4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
6. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
Tykodi SS; Fujii N; Vigneron N; Lu SM; Mito JK; Miranda MX; Chou J; Voong LN; Thompson JA; Sandmaier BM; Cresswell P; Van den Eynde B; Riddell SR; Warren EH
Clin Cancer Res; 2008 Aug; 14(16):5260-9. PubMed ID: 18698046
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?
Neumann E; Engelsberg A; Decker J; Störkel S; Jaeger E; Huber C; Seliger B
Cancer Res; 1998 Sep; 58(18):4090-5. PubMed ID: 9751617
[TBL] [Abstract][Full Text] [Related]
8. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
[TBL] [Abstract][Full Text] [Related]
12. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
13. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
14. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
[TBL] [Abstract][Full Text] [Related]
15. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
16. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.
Lamers CH; Gratama JW; Pouw NM; Langeveld SC; Krimpen BA; Kraan J; Stoter G; Debets R
Hum Gene Ther; 2005 Dec; 16(12):1452-62. PubMed ID: 16390276
[TBL] [Abstract][Full Text] [Related]
17. [Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].
Ringhoffer M; Gschwend JE
Urologe A; 2002 May; 41(3):249-57. PubMed ID: 12132274
[TBL] [Abstract][Full Text] [Related]
18. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
[TBL] [Abstract][Full Text] [Related]
19. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
20. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
